WallStSmart

Biodesix Inc (BDSX)vsThermo Fisher Scientific Inc (TMO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Thermo Fisher Scientific Inc generates 46933% more annual revenue ($45.20B vs $96.10M). TMO leads profitability with a 15.1% profit margin vs -33.3%. TMO earns a higher WallStSmart Score of 62/100 (C+).

BDSX

Avoid

31

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 4.0Quality: 4.5
Piotroski: 4/9Altman Z: -7.79

TMO

Buy

62

out of 100

Grade: C+

Growth: 4.7Profit: 7.0Value: 4.0Quality: 6.0
Piotroski: 3/9Altman Z: 2.13
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BDSXSignificantly Overvalued (-19.0%)

Margin of Safety

-19.0%

Fair Value

$8.70

Current Price

$17.35

$8.65 premium

UndervaluedFair: $8.70Overvalued
TMOSignificantly Overvalued (-40.1%)

Margin of Safety

-40.1%

Fair Value

$331.71

Current Price

$472.80

$141.09 premium

UndervaluedFair: $331.71Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BDSX1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
42.3%10/10

Revenue surging 42.3% year-over-year

TMO1 strengths · Avg: 9.0/10
Market CapQuality
$176.04B9/10

Large-cap with strong market position

Areas to Watch

BDSX4 concerns · Avg: 3.3/10
Price/BookValuation
19.3x4/10

Trading at 19.3x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$161.55M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-349.9%2/10

ROE of -349.9% — below average capital efficiency

TMO3 concerns · Avg: 3.7/10
PEG RatioValuation
1.564/10

Expensive relative to growth rate

P/E RatioValuation
26.0x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : BDSX

The strongest argument for BDSX centers on Revenue Growth. Revenue growth of 42.3% demonstrates continued momentum.

Bull Case : TMO

The strongest argument for TMO centers on Market Cap. Profitability is solid with margins at 15.1% and operating margin at 17.9%.

Bear Case : BDSX

The primary concerns for BDSX are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 7.84 is elevated, increasing financial risk.

Bear Case : TMO

The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

BDSX profiles as a hypergrowth stock while TMO is a mature play — different risk/reward profiles.

TMO carries more volatility with a beta of 0.87 — expect wider price swings.

BDSX is growing revenue faster at 42.3% — sustainability is the question.

TMO generates stronger free cash flow (816M), providing more financial flexibility.

Bottom Line

TMO scores higher overall (62/100 vs 31/100), backed by strong 15.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Biodesix Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company is headquartered in Boulder, Colorado.

Thermo Fisher Scientific Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.

Visit Website →

Want to dig deeper into these stocks?